Community pharmacist–led telephone follow-up enabled close management of everolimus-induced adverse events in an outpatient with metastatic breast cancer

Yokoyama, S.; Yajima, Satoko; Sakai, Chihiro; Yamashita, Shuji; Noguchi, Yoshihiro; Ino, Yoko; Iguchi, Kazuhiro; Teramachi, Hitomi

doi:10.1177/1715163517732088

Cited by 5 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study, we evaluated ADRs using a numerical rating scale. 15 ADRs assessed in community pharmacies are mainly nonhematological. Therefore, patient-reported outcomes such as numerical ratings or visual analog scales can better reflect the daily status.…”

Section: Discussionmentioning

confidence: 99%

Oncology pharmacist contributions to treatment with oral anticancer agents in a Japanese community pharmacy setting

et al. 2018

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Oncology pharmacist contributions to treatment with oral anticancer agents in a Japanese community pharmacy setting

et al. 2018

Self Cite

View full text Add to dashboard Cite

“…Because women represent a considerable percentage of the clientele visiting community pharmacies, pharmacists can play a greater role in increasing awareness of breast cancer, counsel women on the availability of tools to screen for breast cancer and educate patients on the right ways of using their anticancer therapies [ 31 , 32 ]. Pharmacists can also screen for adherence to anticancer therapies, side effects, drug-drug, drug-food, and drug-herb interactions [ 33 – 36 ]. Tanaka et al reported that counseling by pharmacists increased the quality of life and reduced the side effects associated with chemotherapy among patients with breast cancer [ 37 ].…”

Section: Introductionmentioning

confidence: 99%

Pharmacists’ knowledge, attitudes, beliefs, and barriers toward breast cancer health promotion: a cross-sectional study in the Palestinian territories

Shawahna

Awawdeh

2021

BMC Health Serv Res

View full text Add to dashboard Cite

Background Among all cancers, breast cancer is the most prevalent cancer and the leading cause of mortality among women in developing countries including Palestine. Community pharmacists are trusted and easily accessible healthcare providers who could be engaged in breast cancer health promotion. This study was conducted with the aim of exploring knowledge, attitudes, beliefs, and barriers toward breast cancer health promotion among community pharmacists in the Palestinian territories. Methods This study was conducted in a cross-sectional design using a questionnaire among community pharmacists. Knowledge of community pharmacists of breast cancer was tested using a 26-item knowledge test. Attitudes and beliefs of the community pharmacists with regard to breast cancer promotion were explored using 14 items. Barrier to breast cancer health promotion were explored using 9 items. Results Data were collected from 200 community pharmacists. The median knowledge score was 69.2 % with and IQR of 15.2 %. Of the community pharmacists, 67.5 % scored 50 % and above in the knowledge test. Multivariate logistic regression showed that community pharmacists who were female in gender were more likely to score 50 % and above in the knowledge test compared to the community pharmacists who were male in gender (OR = 4.73, 95 % CI of 2.26–9.89). The community pharmacists had positive attitudes toward breast cancer health promotion. There was a significant moderate positive correlation between knowledge and attitudes scores (Spearman’s rho = 0.37, p-value < 0.001). Lack of reimbursement, lack of enough personnel, lack of time, and fear of offending the patients were the main barriers to breast cancer health promotion (percentage of agreement > 60.0 %). Conclusions This study shed light on the role of community pharmacists in breast cancer health promotion. Pharmacists had good knowledge of breast cancer and positive attitudes toward promoting the health of patients with breast cancer. Further studies are still needed to determine how to integrate community pharmacists in the team of healthcare providers caring for patients with breast cancer.

show abstract

“…40 A high proportion of articles described pharmacy services delivered via ‘mobile health’ ( n = 11). 24–26,31–33,37–39,41,42 ‘ Synchronous’ alone was the second most common modality ( n = 5). 23,30,35,36,40 ‘Asynchronous’ alone ( n = 1), 27 ‘asynchronous combined with mobile health’ ( n = 2), 22,28 ‘asynchronous combined with synchronous’ ( n = 1) 29 and ‘synchronous combined with mobile health’ ( n = 1) 34 were the least commonly reported modalities.…”

Section: Resultsmentioning

confidence: 99%

“…Most articles described the use of telepharmacy in terms of ‘patient follow-up, monitoring and counselling’ ( n = 11). 24–26,31–33,37–39,41,42 Other articles focused on ‘Intravenous chemotherapy and sterile compounding’ ( n = 5), 23,27,29,30,40, ‘expanding pharmacy services’ ( n = 4) 22,28,34,35 and ‘remote education’ ( n = 1). 36 The telephone (mobile health) was a common mode of telecommunication used by pharmacists to deliver oncology pharmacy services.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Telepharmacy in oncology care: A scoping review

Gustafson

2020

J Telemed Telecare

View full text Add to dashboard Cite

Introduction Telepharmacy has the potential to enhance pharmacy services in oncology care, especially in remote areas. This scoping review explored the range, critical benefits and barriers of using telepharmacy services in oncology care. Methods The scoping review followed the Arksey and O’Malley’s five-stage framework to identify available evidence. PubMed, CINAHL, Embase, PsycINFO, Ovid MEDLINE and Scopus databases were searched for original research published between 2010 and 2020. The five dimensions of the Alberta Quality Matrix for Health were used to analyse reported outcomes. Results Eligible articles ( n = 21) were analysed. Telepharmacy in oncology care was used for follow-up, monitoring and counselling, intravenous chemotherapy and sterile compounding, expanding availability of pharmacy services, and remote education. Telepharmacy obtained high acceptability among cancer patients ( n = 5) and healthcare professionals ( n = 5), and increased accessibility of pharmaceutical services to underserved cancer populations ( n = 2). Commonly cited effectiveness and safety outcomes were improved patient adherence ( n = 5), increased pharmacy services ( n = 3) and early identification of medication-related problems ( n = 5). Telepharmacy improved efficiency in staffing and workload ( n = 3), and increased cost savings ( n = 3). A shortage of resources ( n = 5), technical problems ( n = 4) and prolonged turnaround time ( n = 4), safety concerns ( n = 2) and patient willingness to pay ( n = 1) were identified barriers to implementing telepharmacy in oncology care. Discussion Despite evidence pointing to the advantages and opportunities for expanding oncology pharmacy services through telepharmacy, certain challenges remain. Further research is needed to investigate safety concerns and patient willingness to pay for telepharmacy services.

show abstract

Community pharmacist–led telephone follow-up enabled close management of everolimus-induced adverse events in an outpatient with metastatic breast cancer

Cited by 5 publications

References 14 publications

Oncology pharmacist contributions to treatment with oral anticancer agents in a Japanese community pharmacy setting

Oncology pharmacist contributions to treatment with oral anticancer agents in a Japanese community pharmacy setting

Pharmacists’ knowledge, attitudes, beliefs, and barriers toward breast cancer health promotion: a cross-sectional study in the Palestinian territories

Telepharmacy in oncology care: A scoping review

Contact Info

Product

Resources

About